KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Current Leases (2017 - 2026)

Biocryst Pharmaceuticals filings provide 9 years of Current Leases readings, the most recent being $317000.0 for Q4 2025.

  • On a quarterly basis, Current Leases fell 82.72% to $317000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $317000.0, a 82.72% decrease, with the full-year FY2025 number at $317000.0, down 82.72% from a year prior.
  • Current Leases hit $317000.0 in Q4 2025 for Biocryst Pharmaceuticals, down from $348000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.5 million in Q2 2023 to a low of $317000.0 in Q4 2025.
  • Median Current Leases over the past 5 years was $1.7 million (2024), compared with a mean of $1.6 million.
  • Biggest five-year swings in Current Leases: soared 117.53% in 2022 and later plummeted 82.72% in 2025.
  • Biocryst Pharmaceuticals' Current Leases stood at $1.8 million in 2021, then fell by 16.66% to $1.5 million in 2022, then rose by 4.88% to $1.6 million in 2023, then grew by 15.41% to $1.8 million in 2024, then plummeted by 82.72% to $317000.0 in 2025.
  • The last three reported values for Current Leases were $317000.0 (Q4 2025), $348000.0 (Q3 2025), and $1.6 million (Q2 2025) per Business Quant data.